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Aminoglycoside antibiotics rapidly enter and kill cochlear hair cells via apical mechanoelectrical
transduction (MET) channels in vitro. In vivo, it remains unknown whether systemically-administered
aminoglycosides cross the blood-labyrinth barrier into endolymph and enter hair cells. Here we show, for
the first time, that systemic aminoglycosides are trafficked across the blood-endolymph barrier and
preferentially enter hair cells across their apical membranes. This trafficking route is predominant
compared to uptake via hair cell basolateral membranes during perilymph infusion.
A
minoglycoside antibiotics, like gentamicin, are widely-used and clinically essential for preventing or
treating Gram-negative bacterial sepsis and tuberculosis
1. However, these drugs carry significant risk
of nephrotoxicity and ototoxicity. In the inner ear, systemic aminoglycosides cross the blood-labyrinth
barrier (BLB), and preferentially killcochlear sensoryhair cells,leading to lifelonghearinglossand deafness
1,the
most prevalent sensory disability worldwide. The cochlear trafficking route(s) by which systemic aminoglyco-
sides reach hair cells has remained an important, yet unanswered, question for over 60 years.
Cochlear hair cells are highly specialized neuro-epithelial cells immersed in two electrochemically distinct
extracellular fluids. Their basolateral membranes are immersed in perilymph that fills the scala tympani and
extracellular spaces of the organ of Corti (Fig. 1). Their apical membranes, including the mechanically-sensitive
stereocilia, are bathed in endolymph. Tight junctions couple all cells lining the endolymphatic space, limiting
paracellularionmovementsbetweenendolymphandperilymph(Fig.1).Endolymphisrichinpotassiumandlow
insodiumandcalcium(157,1.3,0.023 mMrespectively); perilymphhastypicalextracellular levelsofpotassium,
sodium and calcium (4.2, 148, 1.3 mM respectively)
2. The distinctive ionic composition of endolymph is regu-
lated by the stria vascularis that actively transports potassium into endolymph; while the positive endolymphatic
potential (180 mV) drives sodium out through non-specific cation channels in sensory and non-sensory cells.
Thepositiveendolymphaticpotentialalsoprovidesarapidpotassium-richdepolarizingcurrentintohaircellsvia
mechanically-gated mechanoelectrical transduction (MET) channels located at the tips of most hair cell stereo-
cilia
3.TheseMETchannelsarenon-selectivecationchannelspermeabletoaminoglycosidesinvitro
4,5,raisingthe
question ofwhether systemicaminoglycosidesare traffickedinto endolymph priortoentering haircells viaMET
channels in vivo. The most direct route for vascular aminoglycosides to enter endolymph is to cross the tight
junction-coupled endothelialcellsofstrialcapillariesintotheintra-strial spaceandbetakenupbymarginalcells,
prior to clearance into endolymph (Fig. 1). Previous in vivo studies
6,7 revealed that systemic fluorescently-tagged
gentamicin (GTTR) was preferentially taken up by the stria vascularis in the cochlea, providing suggestive, but
inconclusive, evidence for trans-strial trafficking of systemic gentamicin into endolymph and hair cells.
Alternatively, vascular aminoglycosides could traffic through the tight junction-coupled endothelial cells of
non-strial capillaries, in the spiral limbus, basilar membrane and spiral ligament, and load perilymph in the scala
tympani
8, with access to hair cell basolateral membranes (Fig. 1). However, there is little evidence that amino-
glycosides cross hair cell basolateral membranes.
This study provides evidence that systemic gentamicin is trafficked across the blood-endolymph barrier and
preferentially enter hair cells from endolymph in vivo. This has scientific and clinical implications for under-
standing the trafficking mechanisms involved, and developing novel, systemic approaches to preventing
gentamicin-induced ototoxicity in humans.
Results
Todeterminewhichintra-cochlear traffickingrouteaminoglycosidesprimarily followtoenter haircells,weused
bothfluorescently-tagged gentamicin-TexasRed(GTTR) orimmunodetection ofgentamicin (Fig. 2c).Although
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the MET channel and is rapidly localized at hair cell stereocilia fol-
lowing systemic injection, like gentamicin
5,7.
GTTR was given intravenously (1 mg/kg gentamicin base) while
the scala tympani was perfused with artificial perilymph to reduce
GTTR access to the basolateral membranes of hair cells (Fig. 2a).
After 30 minutes, cochlear tissues were systemically perfusion-fixed
and processed for confocal microscopy. Robust GTTR fluorescence
was observed in single optical sections of the stria vascularis and
organofCorti(Fig.2danderespectively),similartocochleaetreated
with systemic GTTR without perilymph wash (Supplementary
Fig. 1). Serum levels of GTTR were ,7.0 mg/ml (n55) 15 minutes
post-injection.
The reciprocal drug delivery paradigm was to infuse 1.4 mg/ml
GTTR in artificial perilymph through the scala tympani for 30 min-
utes, providing GTTR access only to the basolateral membranes of
hair cells (Fig. 2b). This dose was derived from the perilymph-to-
serum aminoglycoside ratio of 20% after a 6-hour i.v. infusion
9, and
likely higher than GTTR levels in perilymph 30 minutes after sys-
temic injection
7. After 30 minutes, there was negligible GTTR fluor-
escence in the stria vascularis and weak fluorescence in hair cells
(Fig. 2f and g respectively). Two batches of GTTR were used, and
cellularfluorescenceintensities werefoundtobesegregatedbybatch
(Fig. 2l). A two-way ANOVA revealed fluorescence variation in the
batches of GTTR used (F[1,12] 5 54.44, p , 0.0001), and more
importantly, fluorescence variation in the GTTR delivery route used
(F[1,12] 5 245.35, p , 0.0001). Post hoc unpaired t-tests (assuming
unequalvariances)confirmedthattheintensityofsystemicGTTRin
hair cells after trafficking across the strial blood-endolymph barrier
was significantly greater than that delivered by scala tympani infu-
sion (p , 0.001, n58; Fig. 2l), indicating that hair cells preferentially
take up GTTR from endolymph.
The weak fluorescence in OHCs following scala tympani infusion
with GTTR (Fig. 2g) was significantly greater than autofluorescence
in OHCs without GTTR exposure (Fig. 2i, 2l;p5 0.0009, n58,
unpaired t-test).In contrast,strial tissues had negligiblefluorescence
following scala tympani infusion of GTTR that was not statistically
different from the extremely weak autofluorescence observed in
untreated stria vasculari imaged at the same laser excitation intens-
ities as in cochleae treated with systemic GTTR (p 5 0.22, n56,
unpaired t-test; Fig. 2f and h), indicating negligible trafficking of
GTTR from perilymph into endolymph via the stria vascularis.
Cochleae treated systemically with hydrolyzed Texas Red also had
negligible fluorescence in hair cells (Supplementary Fig. 1e and f).
Thus, weak fluorescence in hair cells following scala tympani infu-
sion of GTTR indicates that hair cells could take up GTTR across
their basolateral membranes. However, this perilymph trafficking
route is inefficient compared to the robust GTTR fluorescence
observed in the stria vascularis and hair cells following systemic
injection of GTTR implicating trans-strial trafficking into endo-
lymph and hair cells.
Imaging data were collected and analyzed from only sensitive
cochleae with near-normal compound action potentials (CAPs).
Sealing the perfusion catheter occasionally induced mild CAP
threshold shifts in the 12 to 24 kHz region at the base of the cochlea
(e.g. Fig. 2j). However, cochlear sensitivity was well-maintained in
the 2–9 kHz frequency range corresponding to the third cochlear
coil (from the apex) in either experimental paradigm (Fig. 2j and k)
derived from the murine frequency-place map
10. This indicates that
relatively normal cochlear physiological function was maintained
during perfusion (see Discussion).
Since GTTR has a larger molecular mass than gentamicin, we
repeated the same experimental paradigms using gentamicin and
processed thetissues forimmunofluorescence. Theresults werequa-
litatively similar to that with GTTR, with characteristic gentamicin
immunolabeling in hair cells following systemic gentamicin delivery
and perilymph wash (Fig. 3a and b). Following infusion of gentami-
cin through the scala tympani, the immunofluorescence signal was
weak and largely non-specifically distributed throughout the organ
of Corti (i.e., not localized to specific cell types; Fig. 3c and d).
Significantly, CAP thresholds, and thus cochlear sensitivity, were
maintained in the cochlear segment of interest (Fig. 3e and f).
Discussion
Previous studies reported only very low levels of aminoglycosides in
endolymph compared to perilymph in vivo
8,9. The 180-mV endo-
lymphatic potential will electrophoretically drive the cationic ami-
noglycosides present in endolymph through hair cell MET channels,
or other aminoglycoside-permeant cation channels into supporting
cells
4,5,7. This will selectively increase the risk of hair cell toxicity
5,11,
and simultaneously reduce aminoglycoside levels in endolymph
compared to perilymph.
The sensitive hearing monitored by CAP recording during these
experiments indicates that the strial BLB maintained its integrity.
Loss of BLB integrity, or paracellular extravasation of drug-laden
serum into the intra-strial space, would short-circuit the electro-
physiological environment in the cochlea with consequent loss of
both endolymphatic potential and cochlear sensitivity
12,13. This was
notobserved inthese experiments. Furthermore, non-selective, ami-
noglycoside-permeant cation channels cannot be present in the
basolateral membrane of marginal cells
14,15, suggesting that uptake
of aminoglycosides from the intra-strial space into marginal cells
requires active or electrogenic transport across their basolateral
membranes. Identifying this molecular mechanism will initiate
new, systemic strategies to pharmacologically block aminoglycoside
trafficking across the blood-endolymph barrier and into hair cells,
and subsequent cochleotoxicity.
In this study, we used fluorescently-tagged and native genta-
micin. Gentamicin induces both cochleotoxicity and vestibulotoxi-
city, and intratympanic administration of gentamicin is used to
manage Meniere’s disease and vertigo
16. Our data show that, in
relatively normal physiological conditions, hair cells take up little
gentamicin from perilymph compared to trans-strial trafficking of
systemic gentamicin from strial capillaries into endolymph and
Figure 1 | Diagram illustrating potential intra-cochlear trafficking of
systemic aminoglycosides to hair cells. Endolymph trafficking route is
indicated by red dashed arrow, while perilymph trafficking route is
indicatedbybluedashedarrows.Theendolymphaticspaceisencapsulated
by tight junctions depicted by thick black lines. Cochlear capillaries are
locatedinthestriavascularis(a),inthemodiolus(b),onthescalatympani
side of the basilar membrane (c) and within the spiral ligament of the
lateral wall (d).
www.nature.com/scientificreports
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ition
8, and pathophysiological conditions, such as Meniere’s
Disease, could potentially enhance cochlear hair cell uptake of
gentamicin from perilymph
17. Similarly, trafficking of systemic
aminoglycosides to hair cells can also be modulated by acous-
tic trauma, bacterial sepsis or exposure to loop diuretics
18–21.
Although loop diuretics block the sodium-potassium-chloride
co-transporter prevalent on the basolateral membrane or marginal
cells, the integrity of the blood-labyrinth and perilymph-
endolymph barriers are maintained
22. This further implicates a
transcellular trafficking pathway for gentamicin across the strial
blood-endolymph barriers.
In summary, gentamicin is trafficked across the strial BLB
into endolymph preferentially enter hair cells across their apical
membranes, compared to perilymph trafficking, answering a long-
standing question in ototoxicity.
Methods
Animal preparation. Albino guinea pigs (270–500 g, Dunkin-Hartley from Charles
River Laboratories International, Inc.) of either sex with Preyer’s reflex were
anesthetized (ketamine 30 mg/kg and xylazine 5 mg/kg, i.m.). Supplemental doses
were given on recovery of toe-pinch withdrawal reflex. Body temperature was
maintained at 37uC with a servo-regulated heating blanket. Experimental protocols
were approved by the Animal Care and Use Committee at Oregon Health & Science
University (IS00000351).
The animal was supinetoexpose theventralaspectfor surgicalprocedures. The head
was held firmly in place, and a tracheotomy performed to insert a ventilation tube for
unobstructed breathing. A ventral-postauricular approach exposed the left auditory
bulla, with the medial portion of the external auditory canal preserved to allow place-
ment of a sound delivery tube. The temporal bulla was opened to access the cochlea.
Figure 2 | Greater hair cell uptake of GTTR via endolymph trafficking. (a) Diagram illustrating systemic GTTR delivery with scala tympani perilymph
wash. AP, artificial perilymph. (b) Diagram illustrating perilymph infusion with GTTR. (c) Space-fill models of gentamicin and GTTR. Robust GTTR
fluorescence in the stria vascularis (d) and in OHCs, IHCs and pillar cells of the organ of Corti (e) after systemic GTTR delivery with perilymph wash.
Negligible GTTR fluorescence in the stria vascularis (f) and weak fluorescence in the organ of Corti (g) after scala tympani infusion of GTTR. Negligible
autofluorescence (l .615 nm) in the stria vascularis (h) and organ of Corti (i). Scale bars 5 20 mm. All images were acquired and processed using
identical settings. (j) CAPs were largely maintained in the 2–9 kHz region (gray region) corresponding to the third coil from the cochlear apex
10. (k)
Cochlear sensitivity was preserved during scala tympani infusion of GTTR. (l) The intensity of GTTR fluorescence in OHCs was quantified from single
confocalplanes.MorerobustfluorescencewaspresentincochleaeexposedtosystemicGTTRplusperilymphwashcomparedtoscalatympaniinfusionof
GTTR (p , 0.001; n58 per condition, post hoc unpaired t-test). Red (or magenta) circles indicate the same batch of GTTR used among experiments.
AfterscalatympaniinfusionofGTTR,fluorescenceinOHCswasweak,butdetectable,andstatisticallygreaterthaninuntreatedOHCs(p50.0009;n58
per condition, unpaired t-test). A.U., arbitrary units.
www.nature.com/scientificreports
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in the round window niche and fixed on the bulla with carboxylate cement. Tone
bursts (10 ms duration, 1-ms rise/fall) generated using a 16-bit D/A converter
(Tucker Davis Technologies) were delivered to the ear canal to evoke CAPs. The
round window signal was amplified 1,000x by an AC amplifier (CWE Inc, model
BMA-200) and a custom-designed AC amplifier. After A/D conversion and
averaging, the evoked electrical responses were displayed in real time. The minimum
sound level-evoked CAP was documented as threshold at each frequency from 0.5 to
32 kHz. The CAP thresholds were obtained prior to procedures on the cochlea, after
fixing the perfusion inlet catheter and creating the efflux orifice, and after scala
tympani perfusion.
Gentamicin-Texas Red. GTTR was produced in large batches as described earlier
20,
and two batches were used at the same relative fluorescence intensity.
Scala tympani perfusion. Perfusion of the scala tympani with artificial perilymph
was performed to remove GTTR or gentamicin from the scala tympani following
systemic injection, or to infuse aminoglycosides through the scala tympani. An inlet
hole(diameter:70 mm)wasmadeinthescalatympaniofthebasalturn,andtheefflux
orifice (diameter: 80 mm) at the apex turn of the cochlea. The inlet catheter (MRE-
040, Braintree Scientific) with a fine tip (diameter: 60 mm) was inserted into the inlet
hole. Tissue glue fastened the tube in position and sealed the inlet hole. GTTR
(0.5 mg/ml) and gentamicin (100 mg/ml) were dissolved in 0.9% sodium chloride
(Baxter Health Corp.), and further diluted with artificial perilymph (in mM: 125
NaCl, 3.5 KCl, 1.3 CaCl2, 1.5 MgCl2, 0.15 NaH2PO4, 10 HEPES, 5.0 glucose; pH 7.4;
300610 mOsm) as needed prior to use. Perfusates were infused into the scala
tympani for 30 minutes at 2 ml/min using a syringe pump (Harvard Apparatus, PHD
2000), and efflux absorbed using cotton wicks.
Drug delivery. For systemic delivery, 1 mg/kg GTTR (gentamicin base) was injected
into the jugular vein, or 200 mg/kg gentamicin intraperitoneally. Serum levels of
GTTR orgentamicin, obtained using turbidimetricinhibition immunoassay
23 by Lab
Services at OHSU (sensitivity: 0.5 mg/ml)
7 were ,7.0 mg/ml (n55)o r,57 mg/ml
(n53),respectively. Thus,1.4 mg/mlGTTRor11 mg/mlgentamicin wasdeliveredby
scala tympani infusion (20% of serum level by systemic injection
9).
Confocalanalysis.After30minutesofdrugexposureandCAPmeasurement,guinea
pigs were cardiac-perfused with PBS, then 4% formaldehyde in 0.1 M PBS. Cochleae
were excised and fixed overnight, rinsed in PBS, and permeabilized with 0.5% Triton
X-100 for unmasking GTTR fluorescence
24 or gentamicin immunolabeling, as
follows. Fixed gentamicin-treated cochleae were then immunoblocked in 10% goat
serum in PBS for 30 minutes and incubated with 5 mg/ml mouse monoclonal
(Fitzgerald Industries,Concord,MA) gentamicin antisera for 2 hours. After washing
with 1% goat serum in PBS, specimens were further incubated with 20 mg/ml Alexa-
488-conjugated goat anti-mouse antisera (Molecular Probes, Eugene, OR), then
washed,andpost-fixedwith4%formaldehydeforatleast15minutes,asbefore
24.The
stria vascularis and organ of Corti from the third coil were excised and whole-
mounted in VectaShield (Vector Labs, Burlingame, CA) for confocal microscopy
(Bio-Rad MRC 1024 ES).
Imaging and data analysis. Fluorescent images were collected sequentially. Each set
of experimental and control tissues were imaged at the same confocal settings. Two
sites from the third coil of each cochlea were imaged, and identically processed using
AdobePhotoshop.Highresolution xz opticalsections(0.2 mminzdimension)ofthe
whole-mounted stria vascularis were acquired by confocal image acquisition
software. For statistical analysis, GTTR fluorescence intensities were obtained
20 for
two-way ANOVA (delivery route X GTTR batch) and post hoc t-tests to identify any
statistically significant effectofdelivery routes.Thestatistical analysiswasperformed
with Prism (GraphPad Software, Inc.).
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Figure 3 | Gentamicin immunofluorescence also supports a primary
endolymph trafficking route for aminoglycosides. (a) Characteristic
gentamicin immunofluorescence in hair cells in the organ of Corti after
systemic gentamicin plus perilymph wash. Inner hair cell bodies are not in
the same focal plane (b). (c) Gentamicin immunofluorescence had little
cellspecificityintheorganofCortiafterperilymphinfusion.Innerhaircell
bodies are not in the same focal plane (d). Scale bar 5 20 mm. All confocal
images acquired and processed using identical settings. (e) Cochlear
sensitivity was largely maintained in a cochlea receiving systemic
gentamicin plus perilymph wash. Gray area indicates the frequency region
corresponding to the third coil of the guinea pig cochlea. (f) Cochlear
sensitivity was also preserved in a cochlea receiving scala tympani infusion
of gentamicin.
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